November 24th 2024
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).
Study: Sacubitril/Valsartan Led to Fibrosis Improvements in HFrEF
May 20th 2022This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan.
Read More
Chitosan-Based Gel Found to Lower Risk of Wound Infection, Synechia After Nasal Polyps Surgery
May 20th 2022Use of a chitosan-based gel dressing after endoscopic sinus surgery for nasal polyps was found to reduce risk of wound infection and synechia in patients, although no difference was observed regarding granulations.
Read More
Stronger Frameworks Needed to Implement CGM Use at Hospital Discharge
May 20th 2022Continuous glucose monitor (CGM) use as part of a telemedicine program in patients with type 2 diabetes transitioning out of a hospital setting and to a different diabetes therapy was evaluated in this new open-label study.
Read More
Understanding Opioid Use Among Patients With Cancer
May 20th 2022On this episode of Managed Care Cast, Tham Thi Le, PhD, MPH, lead author—then at the University of Maryland at Baltimore, now at AstraZeneca—and Linda Wastila, PhD, MSPH, senior author and the Parke-Davis Chair in Geriatric Pharmacotherapy, Pharmaceutical Health Services Research, at the University of Maryland at Baltimore, discuss the findings of their investigation into opioid use by patients with a new cancer diagnosis and the opioid prescribing practices of their health care providers from 2007 to 2013.
Listen
CLAD, Pulmonary GVHD Have Similar Clinical Traits, Research Needs
May 19th 2022Fine-tuning clinical phenotypes and identifying effective treatments remain challenging in chronic lung allograft dysfunction (CLAD) after lung transplantation and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation.
Read More
Dr Elaine Siegfried Discusses Skin Color, Socioeconomic Implications of Atopic Dermatitis Management
May 19th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
Watch
Neil Goldfarb Previews Theme, Potential Takeaways of 2022 GPBCH Annual Conference
May 18th 2022Neil Goldfarb, president and chief executive officer of Greater Philadelphia Business Coalition on Health (GPBCH), provides an overview of the core discussion points and other aspects in-person attendees can look forward to at the 2022 GPBCH Annual Conference.
Watch
Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis
May 17th 2022Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Read More
Trends Show Uptake of SUD Treatment Has Room for Improvement
May 17th 2022On this episode of Managed Care Cast, we speak with one of the authors of a paper published this month in Health Affairs about the utilization of substance use disorder treatment (SUD) services between 2010 and 2019, and why more needs to be done to get more individuals into treatment.
Listen
Contributor: The Convergence of Value-Based Care and Lab Testing Growth
May 17th 2022Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.
Read More
Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis
May 16th 2022Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.
Read More
FDA to make an announcement regarding importation of baby formula; first-line use of nivolumab and ipilimumab vs standard of care chemotherapy fails to meet primary end point of overall survival in phase 3 CheckMate 901 trial; study finds link between antibiotic prescriptions and inflammatory bowel disease diagnosis in older adults.
Read More
Superior Clinical Outcomes Seen in HFrEF With Early Initiation of Sacubitril/Valsartan
May 16th 2022Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.
Read More
RAS Inhibitors May Hold Potential as Preventive for Acute Chest Syndrome in Sickle Cell Disease
May 15th 2022A retrospective study assessed hospital readmission rates in patients with sickle cell disease and acute chest syndrome who took angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers vs those who did not.
Read More
Jayson Slotnik Discusses Using Payment Models to Address Health Equity
May 13th 2022While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Watch
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Watch
Study Finds Rural Residence May Adversely Influence Lung Cancer Screening Among Veterans
May 12th 2022Veterans residing in rural areas were less likely to complete annual repeat lung cancer screenings compared with those living in a nonrural location, with reduced uptake of initial lung cancer screening also found among eligible veterans in rural vs nonrural locations.
Read More